Empagliflozin benefits adults hospitalised for acute heart failure

Phase III trial shows that adults hospitalised for acute heart failure were 36 percent more likely to experience a clinical benefit if initiated on empagliflozin.

Related Keywords

Netherlands ,Groningen ,Adriaan Voors ,Waheed Jamal ,Eli Lilly ,University Medical Center ,European Union ,Boehringer Ingelheim ,National Readmission Database ,Kansas City Cardiomyopathy Questionnaire ,Empulse Principal ,National Readmission ,Corporate Vice President ,Cardiometabolic Medicine ,